Suchergebnisse - "Rimassa, Lorenza"

PubPharm (370)

51

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

enthalten in: JHEP reports | January 2023

von Scheiner, B. | Roessler, D. | Phen, S. | +35

52

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma : An international observational study

enthalten in: Liver International | 2023

von Talbot, T. | D'Alessio, A. | Pinter, M. | +33

53

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer : An early exploratory analysis of real‐world data

enthalten in: Liver International | 2023

von Rimini, M. | Fornaro, L. | Lonardi, S. | +37

54

Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization

enthalten in: Journal of clinical medicine | 2022

von Masetti, C. | Pugliese, N. | Lofino, L. | +10

55

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

enthalten in: Journal of cancer research and clinical oncology | 2022

von Persano, M. | Rimini, M. | Tada, T. | +77

56

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

enthalten in: Journal of cancer research and clinical oncology | 2022

von Persano, M. | Rimini, M. | Tada, T. | +77

57

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

enthalten in: Journal of cancer research and clinical oncology | 2022

von Persano, M. | Rimini, M. | Tada, T. | +77

58

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

enthalten in: Cancers | 2022

von Wu, Y. | Fulgenzi, C. | D'Alessio, A. | +32

59

Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC : A Phase III Trial (NCT02323360)

enthalten in: Current oncology (Toronto, Ont.) | 2022

von Comito, T. | Loi, M. | Franzese, C. | +14

60

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Vithayathil, M. | D'Alessio, A. | Fulgenzi, C. | +32

CommentIn: Liver Int. 2022 Nov;42(11):2352-2353. - PMID 36162086